Atossa Therapeutics Files 8-K on Executive Changes
Ticker: ATOS · Form: 8-K · Filed: Oct 14, 2025 · CIK: 1488039
| Field | Detail |
|---|---|
| Company | Atossa Therapeutics, INC. (ATOS) |
| Form Type | 8-K |
| Filed Date | Oct 14, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.18, $415,900 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-changes, regulation-fd
Related Tickers: ATOS
TL;DR
ATOS board/exec shakeup, check the details.
AI Summary
Atossa Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes a Regulation FD Disclosure.
Why It Matters
Changes in a company's board of directors and executive officers can signal shifts in strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Executive and director changes can introduce uncertainty regarding company direction and strategy.
Key Players & Entities
- Atossa Therapeutics, Inc. (company) — Registrant
- October 14, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 206.588.0256 (phone_number) — Business Phone
FAQ
What specific executive or director positions were affected by the changes reported in this 8-K?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific names and roles are not detailed in the provided excerpt.
Are there any details about new compensatory arrangements for officers mentioned in the filing?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item of disclosure, but the specifics of these arrangements are not provided in the excerpt.
What is the significance of the 'Regulation FD Disclosure' mentioned in the filing?
A Regulation FD Disclosure ensures that material non-public information is broadly disseminated to the public, preventing selective disclosure to certain investors.
When was Atossa Therapeutics, Inc. incorporated, and in which state?
Atossa Therapeutics, Inc. was incorporated in Delaware.
What is the principal executive office address for Atossa Therapeutics, Inc.?
The principal executive offices are located at 10202 5th Avenue NE, Suite 200, Seattle, Washington 98125.
Filing Stats: 1,501 words · 6 min read · ~5 pages · Grade level 10.8 · Accepted 2025-10-14 07:50:28
Key Financial Figures
- $0.18 — ge on which registered Common Stock , $0.18 par value ATOS The Nasdaq Capital M
- $415,900 — will receive an initial base salary of $415,900 and the opportunity to receive an annua
Filing Documents
- atos-20251014.htm (8-K) — 68KB
- atos-ex10_1.htm (EX-10.1) — 122KB
- atos-ex99_1.htm (EX-99.1) — 16KB
- img248274862_0.jpg (GRAPHIC) — 5KB
- 0001193125-25-238065.txt ( ) — 367KB
- atos-20251014.xsd (EX-101.SCH) — 45KB
- atos-20251014_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On October 14, 2025, the Company issued a press release announcing the appointment of Mr. Daniel and the transition of Ms. Rees. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as otherwise expressly stated in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description of Exhibit 10.1 Employment Agreement by and between Atossa Therapeutics, Inc. and Mark Daniel, effective October 14, 2025. 99.1 Press release, dated October 14, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Atossa Therapeutics, Inc. Date: October 14, 2025 By: /s/ Steven C. Quay Steven C. Quay, M.D., Ph.D. Chairman, President and Chief Executive Officer